An irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been approved for first-line treatment of non-small cell lung cancer (NSCLC) with certain EGFR mutations.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content